Literature DB >> 20009774

Impact of postoperative radiation after esophagectomy for esophageal cancer.

David Schreiber1, Justin Rineer, Dan Vongtama, Angela Wortham, Peter Han, David Schwartz, Kwang Choi, Marvin Rotman.   

Abstract

INTRODUCTION: Though postoperative radiation for esophageal cancer is offered in selected cases, there is conflicting evidence as to whether it improves overall survival (OS). We performed a retrospective analysis using the Surveillance Epidemiology and End Results database to analyze the impact of adjuvant radiation in a large cohort of patients.
METHODS: From 1998 to 2005, patients diagnosed with stage T3-4N0M0 or T1-4N1M0 esophageal adenocarcinoma (AC) or squamous cell carcinoma (SCC) who were definitively treated with esophagectomy, with or without postoperative radiation, were selected. Kaplan-Meier and Cox regression analysis were used to compare OS and disease-specific survival (DSS).
RESULTS: A total of 1046 patients met the selection criteria: 683 (65.3%) received surgery alone and 363 (34.7%) received postoperative radiation. For American Joint Committee on Cancer stage III esophageal carcinoma (T3N1M0 or T4N0-1M0), there was significant improvement in median and 3-year OS (p < 0.001) and DSS (p < 0.001), respectively. This benefit was present for both SCC and AC. However, for American Joint Committee on Cancer stages IIA and IIB disease there was no significant differences in OS or DSS. Multivariate analysis revealed that postoperative radiation was the most significant predictor for improved OS (hazard ratio 0.70, 95% confidence interval 0.59-0.83, p < 0.001).
CONCLUSIONS: This large population-based review supports the use of postoperative radiation for stage III SCC and AC of the esophagus. Given the retrospective nature of this study, until appropriately powered randomized trials confirm these results, caution should be used before broadly applying these findings in clinical practice.

Entities:  

Mesh:

Year:  2010        PMID: 20009774     DOI: 10.1097/JTO.0b013e3181c5e34f

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  39 in total

1.  The impact of adjuvant radiotherapy on radically resected T3 esophageal squamous cell carcinoma.

Authors:  Shao-bin Chen; Hong-rui Weng; Geng Wang; Di-tian Liu; Hua Li; Hao Zhang; Yu-ping Chen
Journal:  J Cancer Res Clin Oncol       Date:  2015-09-02       Impact factor: 4.553

2.  Recurrence risk model for esophageal cancer after radical surgery.

Authors:  Jincheng Lu; Hua Tao; Dan Song; Cheng Chen
Journal:  Chin J Cancer Res       Date:  2013-10       Impact factor: 5.087

Review 3.  Postoperative radiation therapy of pT2-3N0M0 esophageal carcinoma-a review.

Authors:  Yijun Luo; Xiaoli Wang; Jinming Yu; Bin Zhang; Minghuan Li
Journal:  Tumour Biol       Date:  2016-09-18

4.  Update: modern approaches to the treatment of localized esophageal cancer.

Authors:  James Welsh; Arya Amini; Anna Likhacheva; Jeremy Erasmus J; Daniel Gomez; Marta Davila; Reza J Mehran; Ritsuko Komaki; Zhongxing Liao; Wayne L Hofstetter; Jeffrey Lee H; Manoop S Bhutani; Jaffer A Ajani
Journal:  Curr Oncol Rep       Date:  2011-06       Impact factor: 5.075

5.  Radiation therapy in the postoperative management of esophageal cancer.

Authors:  Salma K Jabbour; Charles R Thomas
Journal:  J Gastrointest Oncol       Date:  2010-12

Review 6.  Esophageal cancer management controversies: Radiation oncology point of view.

Authors:  Patricia Tai; Edward Yu
Journal:  World J Gastrointest Oncol       Date:  2014-08-15

7.  Influence of sex on the survival of patients with esophageal cancer.

Authors:  Pierre Bohanes; Dongyun Yang; Ruchika S Chhibar; Melissa J Labonte; Thomas Winder; Yan Ning; Armin Gerger; Léonor Benhaim; David Paez; Takeru Wakatsuki; Fotios Loupakis; Rita El-Khoueiry; Wu Zhang; Heinz-Josef Lenz
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544

8.  Postoperative Radiotherapy in Pathological T2-3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study.

Authors:  Wei Deng; Jinsong Yang; Wenjie Ni; Chen Li; Xiao Chang; Weiming Han; Zongmei Zhou; Dongfu Chen; Qinfu Feng; Jun Liang; Jima Lv; Xiaozhen Wang; Xin Wang; Lei Deng; Wenqing Wang; Nan Bi; Tao Zhang; Yexiong Li; Shugeng Gao; Qi Xue; Yousheng Mao; Kelin Sun; Xiangyang Liu; Dekang Fang; Dali Wang; Jian Li; Jun Zhao; Kang Shao; Zhishan Li; Xinjie Chen; Lei Han; Lifang Wang; Jie He; Zefen Xiao
Journal:  Oncologist       Date:  2020-02-21

9.  Postoperative Adjuvant Therapy Versus Surgery Alone for Stage IIB-III Esophageal Squamous Cell Carcinoma: A Phase III Randomized Controlled Trial.

Authors:  Wenjie Ni; Shufei Yu; Zefen Xiao; Zongmei Zhou; Dongfu Chen; Qinfu Feng; Jun Liang; Jima Lv; Shugeng Gao; Yousheng Mao; Qi Xue; Kelin Sun; Xiangyang Liu; Dekang Fang; Jian Li; Dali Wang; Jun Zhao; Yushun Gao
Journal:  Oncologist       Date:  2021-08-19

10.  Analysis of new N-category on prognosis of oesophageal cancer with positive lymph nodes in a Chinese population.

Authors:  Yaping Xu; Youhua Jiang; Xinmin Yu; Qixun Chen; Xinming Zhou; Weimin Mao
Journal:  Radiol Oncol       Date:  2013-02-01       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.